INTRODUCTION
• Renal osteodystrophy is an integral component of chronic kidney disease-mineral/bone disorder (CKD-MBD). CKD-MBD is strongly associated with unacceptable morbidity and mortality in end-stage kidney disease (ESKD). 1 • Activin A is a transforming growth factor-β superfamily protein that is found at high levels in bone; its signaling is through the type II activin A receptor (ActRIIA). [2] [3] [4] • Inhibin, an inhibitor of activin A signaling, is produced in the ovaries and stimulates bone growth. 2, 5 • Decreased inhibin expression is associated with post-menopausal bone loss.
5
-Non-clinical studies suggest that RAP-011 (the murine ActRIIA-IgG1 analog to the human investigational product sotatercept) modulates the balance between bone formation and bone resorption activity by blocking signaling through ActRIIA. 2, 6, 7 -In a 5/6 nephrectomy mouse model of CKD that exhibits bone loss, bone mass measurements were significantly improved with 8 weeks of RAP-011 treatment compared with the control mice. 6 • A mouse model of ldlr-/-high-fat, 5/6 nephrectomy recapitulates many aspects of CKD-MBD, including vascular calcification, hyperphosphatemia, elevated FGF-23, and hyperparathyroidism. 8 • Despite hyperparathyroidism, loss of bone mass is associated with adynamic bone disease assessed by histomorphometry in the CKD mice. 8 • In the ldlr-/-high-fat fed, 5/6 nephrectomy model of vascular calcification, RAP-011 inhibited Smad-dependent signaling, blocked aortic osteoblastic transition, increased vascular smooth muscle protein levels, and decreased CKD-stimulated vascular calcification.
9
• The goal of this study was to evaluate the role of activin signaling in the pathogenesis of renal osteodystrophy.
METHODS
• The 4 different groups of mice used in this study are described in Table 1 .
• Sham-operated ldlr-/-high-fat fed mice (n=12) manifest diabetes and hypercholesterolemia. CKD with hyperphosphatemia, elevated FGF-23, and 60% reduction in glomerular filtration rate (CKD-3) was induced by 5/6 nephrectomy at 14 weeks of age in the ldlr-/-high-fat fed mice, and is a model of atherosclerotic vascular calcification.
• CKD-3 mice were injected intraperitoneally weekly beginning at 22 weeks of age with vehicle (CKD-3 V; n=13) or RAP-011 10 mg/kg (CKD-3 R; n=15) and studied at 28 weeks by skeletal histomorphometry. Results for CKD-3 mice were compared with wild type (WT) mice (n=5) and sham (n=12). 
RESULTS
• Activin A levels were increased in a model of CKD (Figure 1) , making the use of RAP-011 as an activin inhibitor a viable therapeutic approach.
9
• Kidney function was reduced to a degree that is analogous to human stage 3 CKD (CKD-3) in the 2 groups of ldlr-/-ablative CKD mice studied. Table 2 ). This effect of ldlr-/-and high-fat diet has been reported previously. 10 • Induction of CKD-3 caused high turnover bone disease in CKD-3 V mice (unlike prior studies using this model with less severe CKD) 8 and lower BV/TV (11.22%) compared with WT (12.90%), and this was reversed by 6 weeks of RAP-011 treatment (BV/TV: 13.28%) in CKD-3 R ( Table 2) . Similar trends were noted in trabecular thickness.
• CKD-3 V-treated mice demonstrated higher erosion surface/bone surface and higher osteoclast number/100 mm bone length (1.83% and 62.32/100 mm, respectively) compared with sham (1.05% and 33.40/100 mm), which were mitigated by RAP-011 (1.23% and 38.37/100 mm) in CKD-3 R mice ( Table 2 ).
• CKD-3 V-treated mice also demonstrated higher osteoblast surface/ bone surface and higher osteoblast number/100 mm bone length (1.58% and 110.63/100 mm respectively; P<0.05) compared with WT (not shown) or sham (Figures 2 and 3 ).
• RAP-011 significantly reduced both osteoblast surface/bone surface and osteoblast number/100 mm bone length (0.68% and 43.17/ 100 mm, respectively; P<0.05) in CKD-3 R-treated mice compared with CKD-3 V-treated mice (Figures 2 and 3 ).
• Despite the significant reduction in the osteoblast number relative to CKD-3 V, the mineral apposition rate with RAP-011 treatment was maintained (0.42 and 0.40 µm/day, respectively), with a significantly higher bone formation rate/osteoblast (0.17 vs. 0.48 µm 3 /100 cells/ year, respectively; P<0.05 vs. vehicle), which was similar to WT (0.42 µm 3 /100 cells/year) (Figure 4 ).
• RAP-011 did not affect hyperphosphatemia or FGF-23 levels. 
CONCLUSIONS
• Increased circulating activin contributes to the high turnover osteodystrophy associated with CKD-3 in mice.
• Activin inhibition with RAP-011, an ActRIIA ligand trap, increased BV in CKD-3 by inhibiting bone resorption and bone formation rate/osteoblast, counteracting the negative effects of CKD.
